JP5643227B2 - 炭酸ランタンの崩壊製剤 - Google Patents

炭酸ランタンの崩壊製剤 Download PDF

Info

Publication number
JP5643227B2
JP5643227B2 JP2011546449A JP2011546449A JP5643227B2 JP 5643227 B2 JP5643227 B2 JP 5643227B2 JP 2011546449 A JP2011546449 A JP 2011546449A JP 2011546449 A JP2011546449 A JP 2011546449A JP 5643227 B2 JP5643227 B2 JP 5643227B2
Authority
JP
Japan
Prior art keywords
lanthanum carbonate
dosage form
pharmaceutical dosage
lanthanum
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011546449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515723A5 (cg-RX-API-DMAC7.html
JP2012515723A (ja
Inventor
ブラム ワークス、アンドレア
ブラム ワークス、アンドレア
ツイスト、ジョン
ノエ、オケイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Inc
Original Assignee
Mylan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Inc filed Critical Mylan Inc
Publication of JP2012515723A publication Critical patent/JP2012515723A/ja
Publication of JP2012515723A5 publication Critical patent/JP2012515723A5/ja
Application granted granted Critical
Publication of JP5643227B2 publication Critical patent/JP5643227B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011546449A 2009-01-21 2010-01-21 炭酸ランタンの崩壊製剤 Expired - Fee Related JP5643227B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14616209P 2009-01-21 2009-01-21
US61/146,162 2009-01-21
PCT/US2010/021573 WO2010085520A1 (en) 2009-01-21 2010-01-21 Disintegrable formulations of lanthanum carbonate

Publications (3)

Publication Number Publication Date
JP2012515723A JP2012515723A (ja) 2012-07-12
JP2012515723A5 JP2012515723A5 (cg-RX-API-DMAC7.html) 2013-02-14
JP5643227B2 true JP5643227B2 (ja) 2014-12-17

Family

ID=42356194

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546449A Expired - Fee Related JP5643227B2 (ja) 2009-01-21 2010-01-21 炭酸ランタンの崩壊製剤

Country Status (10)

Country Link
US (1) US8962036B2 (cg-RX-API-DMAC7.html)
EP (1) EP2389070B1 (cg-RX-API-DMAC7.html)
JP (1) JP5643227B2 (cg-RX-API-DMAC7.html)
CA (1) CA2748496C (cg-RX-API-DMAC7.html)
ES (1) ES2433076T3 (cg-RX-API-DMAC7.html)
PL (1) PL2389070T3 (cg-RX-API-DMAC7.html)
PT (1) PT2389070E (cg-RX-API-DMAC7.html)
SI (1) SI2389070T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010085520A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105577B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0640812B2 (ja) 1987-10-28 1994-06-01 雪印乳業株式会社 醗酵室

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263119B2 (en) 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
WO2016051609A1 (ja) * 2014-10-02 2016-04-07 東和薬品株式会社 粒度調整された炭酸ランタン水和物からなる医薬
JP2016147827A (ja) * 2015-02-12 2016-08-18 株式会社三和化学研究所 炭酸ランタン水和物を含有する医薬製剤
CN112724039A (zh) 2015-04-20 2021-04-30 艾德凡斯化学公司 包括烷基肟的涂料组合物
EP4061340A4 (en) 2019-11-21 2023-08-09 Santa Farma Ilaç Sanayi A.S. ORAL SOLID PHARMACEUTICAL COMPOSITIONS WITH LANTANHANE CARBONATE OCTAHYDRATE
CN115813867B (zh) * 2022-12-01 2024-05-24 山东齐都药业有限公司 碳酸镧冻干片及其制备方法
JP2025044388A (ja) * 2023-09-20 2025-04-02 株式会社東芝 酸性ガス除去方法、酸性ガス吸収剤、および酸性ガス除去装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3371531B2 (ja) * 1994-04-20 2003-01-27 株式会社豊田中央研究所 触媒の製造方法
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US20040161474A1 (en) 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
DK2792363T3 (da) * 2003-08-26 2016-09-26 Shire Biopharmaceuticals Holdings Ireland Ltd Farmaceutisk formulering, der omfatter lanthanforbindelser
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
WO2007022466A2 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Hyperphosphatemia in domestic animals: compositions and methods of treatment
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0640812B2 (ja) 1987-10-28 1994-06-01 雪印乳業株式会社 醗酵室

Also Published As

Publication number Publication date
SI2389070T1 (sl) 2013-11-29
PL2389070T3 (pl) 2014-01-31
ES2433076T3 (es) 2013-12-09
HK1163452A1 (en) 2012-09-14
EP2389070A1 (en) 2011-11-30
EP2389070B1 (en) 2013-07-31
PT2389070E (pt) 2013-10-21
CA2748496A1 (en) 2010-07-29
US20110280967A1 (en) 2011-11-17
US8962036B2 (en) 2015-02-24
WO2010085520A1 (en) 2010-07-29
EP2389070A4 (en) 2012-07-11
CA2748496C (en) 2019-02-26
JP2012515723A (ja) 2012-07-12
ZA201105577B (en) 2014-01-29

Similar Documents

Publication Publication Date Title
JP2012515723A (ja) 炭酸ランタンの崩壊製剤
RU2563819C2 (ru) Лекарственные формы цитрата железа (iii)
KR101438071B1 (ko) 약학 조성물
CN1871018B (zh) 包含镧化合物的药物制剂
ES2820737T3 (es) Composición farmacéutica que comprende partículas de quelante de fosfato
EP1128815A1 (en) Process for preparing oral calcium compositions
WO2000078292A1 (en) Quickly disintegrating solid preparations
JPH10502390A (ja) 医薬品用の徐放性マトリックス
CN101099729B (zh) 含盐酸氨溴索与沙丁胺醇活性成分的口服固体制剂
JP2001513801A (ja) パラセタモールを含む嚥下錠剤
CN103826610B (zh) (三甲氧基苯氨基)嘧啶基配制品
EP2395972A1 (en) Particulate composition and the method of making the same
CN101284011B (zh) 一种齐墩果酸口腔崩解片及其制备方法
KR102206535B1 (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
WO2019012552A1 (en) COMPOSITIONS OF FERRIC ORGANIC COMPOUNDS
HK1163452B (en) Disintegrable formulations of lanthanum carbonate
JP3746524B2 (ja) 制酸剤組成物およびそれを用いた医薬組成物
CN1981746A (zh) 盐酸氟西汀口腔崩解片及其制备方法
KR20150096787A (ko) Ｎ-[5-[2-(3,5-디메톡시페닐)에틸]-2ｈ-피라졸-3-일]-4-[(3ｒ,5ｓ)-3,5-디메틸피페라진-1-일]벤즈아미드의 약학 제제
KR101509489B1 (ko) 발사르탄을 함유하는 고형 경구제형의 제조 방법
JP2010513516A (ja) 固形剤の湿式顆粒化処方物中の崩壊促進剤
JPH11349492A (ja) 苦味を低減した経口用医薬組成物および苦味低減化方法
EP2829269A1 (en) Orally Disintegrating Tablet Formulation Comprising Flurbiprofen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141014

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141030

R150 Certificate of patent or registration of utility model

Ref document number: 5643227

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees